Mankind Pharma Ltd. (MANKIND) Price & Analysis

Compare

13 Followers

MANKIND Stock Chart & Stats

₹2202.55

-₹40.15(-1.38%)

At close: Jan 08 4:00 PM EST

₹2202.55

-₹40.15(-1.38%)

Day’s Range― - ―

52-Week Range₹2,016.00 - ₹2,726.75

Previous CloseN/A

Volume302.66K

Average Volume (3M)10.08K

Market Cap

₹856.65B

Enterprise Value₹913.74B

Total Cash (Recent Filing)₹25.25B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)48.1

Beta0.59

Next Earnings

Jun 02, 2026

EPS Estimate

11.55

Next Dividend Ex-DateN/A

Dividend Yield0.04%

Share Statistics

EPS (TTM)12.50

Shares Outstanding412,805,080

10 Day Avg. Volume5,924

30 Day Avg. Volume10,081

Financial Highlights & Ratios

PEG Ratio16.80

Price to Book (P/B)6.94

Price to Sales (P/S)8.15

P/FCF Ratio50.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹2,700.00

Price Target Upside22.59% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthConsistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Profit MarginsHigh profit margins reflect efficient cost management and pricing power, contributing to sustainable profitability.

Cash Flow GenerationStrong cash flow generation supports reinvestment in growth opportunities and provides financial flexibility.

Bears Say

EPS DeclineA decline in EPS suggests potential challenges in maintaining profitability, which could affect investor confidence and future growth.

Valuation ConcernsHigh valuation ratios can limit upside potential and may lead to corrections if growth expectations are not met.

Bearish MomentumProlonged bearish momentum could impact investor sentiment and hinder stock performance, affecting capital raising ability.

Mankind Pharma Ltd. News

Mankind Pharma Publishes Q3 and Nine-Month FY26 Earnings Call Transcript

The latest update is out from Mankind Pharma Ltd. ( ($IN:MANKIND) ). Mankind Pharma Limited has released the...

14d ago

Mankind Pharma Challenges GST Order on Subsidiary Merger

Mankind Pharma Ltd. ( ($IN:MANKIND) ) just unveiled an announcement. Mankind Pharma Ltd. has announced that it received...

3M ago

Mankind Pharma Reports Strong Financial Performance for Q2 and H1 2025

The latest update is out from Mankind Pharma Ltd. ( ($IN:MANKIND) ). Mankind Pharma Ltd. announced its unaudited...

4M ago

Mankind Pharma Receives ESG Rating Score of 69

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has issued an update. Mankind Pharma Ltd. has received an ESG rating...

4M ago

Mankind Pharma Schedules Investor Conference Call for Q2 & H1 FY26

An update from Mankind Pharma Ltd. ( ($IN:MANKIND) ) is now available. Mankind Pharma Limited has announced an...

4M ago

Mankind Pharma’s MKP10241 Study: A Potential Game-Changer for Obesity and Diabetes Treatment?

Mankind Pharma Ltd. (($IN:MANKIND)) announced an update on their ongoing clinical study. Mankind Pharma Ltd. is conducting a...

4M ago

Mankind Pharma Reports No Share Dematerialisation Requests for Q3 2025

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has provided an announcement. Mankind Pharma Limited has announced that it has...

5M ago

Mankind Pharma Ltd. Sees Withdrawal of CGST Penalty

An announcement from Mankind Pharma Ltd. ( ($IN:MANKIND) ) is now available. Mankind Pharma Ltd. announced that the...

6M ago

Mankind Pharma to Engage with Investors at Jefferies India Forum

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has provided an update. Mankind Pharma Ltd. has announced its participation in...

6M ago

Mankind Pharma Receives ‘Adequate’ ESG Rating from Crisil

Mankind Pharma Ltd. ( ($IN:MANKIND) ) has shared an update. Mankind Pharma Ltd. has received an ESG rating...

6M ago

MANKIND FAQ

What was Mankind Pharma Ltd.’s price range in the past 12 months?

Mankind Pharma Ltd. lowest stock price was ₹2016.00 and its highest was ₹2726.75 in the past 12 months.

What is Mankind Pharma Ltd.’s market cap?

Mankind Pharma Ltd.’s market cap is ₹856.65B.

When is Mankind Pharma Ltd.’s upcoming earnings report date?

Mankind Pharma Ltd.’s upcoming earnings report date is Jun 02, 2026 which is in 99 days.

How were Mankind Pharma Ltd.’s earnings last quarter?

Mankind Pharma Ltd. released its earnings results on Feb 03, 2026. The company reported ₹12.5 earnings per share for the quarter, beating the consensus estimate of ₹12.038 by ₹0.462.

Is Mankind Pharma Ltd. overvalued?

According to Wall Street analysts Mankind Pharma Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mankind Pharma Ltd. pay dividends?

Mankind Pharma Ltd. pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 0.04%. See more information on Mankind Pharma Ltd. dividends here

What is Mankind Pharma Ltd.’s EPS estimate?

Mankind Pharma Ltd.’s EPS estimate is 11.55.

How many shares outstanding does Mankind Pharma Ltd. have?

Mankind Pharma Ltd. has 412,805,080 shares outstanding.

What happened to Mankind Pharma Ltd.’s price movement after its last earnings report?

Mankind Pharma Ltd. reported an EPS of ₹12.5 in its last earnings report, beating expectations of ₹12.038. Following the earnings report the stock price went up 4.296%.

Which hedge fund is a major shareholder of Mankind Pharma Ltd.?

Currently, no hedge funds are holding shares in IN:MANKIND

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Mankind Pharma Ltd.

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. Mankind Pharma Limited was founded in 1986 and is based in New Delhi, India.

Mankind Pharma Ltd. (MANKIND) Earnings & Revenues

Historic Earnings Reports

MANKIND Stock 12 Month Forecast

Average Price Target

₹2,700.00

▲(22.59% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2066":"₹2,066","2801":"₹2,801","2249.75":"₹2,249.8","2433.5":"₹2,433.5","2617.25":"₹2,617.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.80K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.70K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.60K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2066,2249.75,2433.5,2617.25,2801],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2067.1,2123.476923076923,2179.853846153846,2236.230769230769,2292.607692307692,2348.984615384615,2405.3615384615387,2461.7384615384617,2518.1153846153848,2574.492307692308,2630.869230769231,2687.246153846154,2743.623076923077,{"y":2800,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2067.1,2115.7846153846153,2164.4692307692308,2213.153846153846,2261.8384615384616,2310.523076923077,2359.207692307692,2407.8923076923074,2456.576923076923,2505.2615384615383,2553.9461538461537,2602.630769230769,2651.3153846153846,{"y":2700,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2067.1,2108.0923076923077,2149.0846153846155,2190.076923076923,2231.0692307692307,2272.0615384615385,2313.0538461538463,2354.0461538461536,2395.0384615384614,2436.0307692307692,2477.023076923077,2518.0153846153844,2559.007692307692,{"y":2600,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2435.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2289.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2455.73,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2462.73,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2413.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2287.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2561.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2518.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2438.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2382.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2229.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2163.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2067.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >